BioNTech SE
NASDAQ:BNTX

Watchlist Manager
BioNTech SE Logo
BioNTech SE
NASDAQ:BNTX
Watchlist
Price: 119.35 USD 1.14% Market Closed
Market Cap: $28.7B

Operating Margin

-22.2%
Current
Declining
by 28.7%
vs 3-y average of 6.5%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-22.2%
=
Operating Income
€-822.8m
/
Revenue
€3.2B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-22.2%
=
Operating Income
$-822.8m
/
Revenue
€3.2B

Peer Comparison

Country Company Market Cap Operating
Margin
DE
BioNTech SE
NASDAQ:BNTX
28.7B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
394.7B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44.1B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.5B USD
Loading...

Market Distribution

Lower than 88% of companies in Germany
Percentile
12th
Based on 3 747 companies
12th percentile
-22.2%
Low
-61 459.6% — 0.7%
Typical Range
0.7% — 9.8%
High
9.8% — 94 540%
Distribution Statistics
Germany
Min -61 459.6%
30th Percentile 0.7%
Median 4.5%
70th Percentile 9.8%
Max 94 540%

BioNTech SE
Glance View

BioNTech SE, founded in 2008 by the visionary duo Ugur Sahin and Özlem Türeci, has gradually emerged as a shining beacon in the world of biotechnology. Situated in Mainz, Germany, BioNTech carved its niche by focusing on the development of personalized therapies for cancer and other serious diseases. The company’s core competence lies in utilizing messenger RNA (mRNA) technology, which allows it to instruct the body to produce proteins that can stimulate an immune response. This technology became a game changer, not only in the cancer arena but also expanded its reach into infectious diseases, showcasing a broader horizon of possibilities. BioNTech’s ability to leverage its research expertise in mRNA placed it at the forefront of scientific innovation, demonstrating breathtaking adaptability and ingenuity. The company's business model thrives on strategic partnerships and collaborations, which bolster both its scientific output and financial standing. One of its most celebrated partnerships is with Pfizer, a collaboration that led to the development of the groundbreaking COVID-19 vaccine, Comirnaty. This collaboration thrust BioNTech onto the global stage, underscoring its capacity to swiftly respond to urgent health crises while generating substantial revenue. The success and distribution of the vaccine not only provided a significant boost to BioNTech’s financials but also validated its platform as powerful and versatile. By continually investing in research and development, both independently and through alliances, BioNTech aims to solidify its position as a leader in the evolving biotech landscape, paving the way for future therapies that could redefine medical treatments.

BNTX Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-22.2%
=
Operating Income
€-822.8m
/
Revenue
€3.2B
What is BioNTech SE's current Operating Margin?

The current Operating Margin for BioNTech SE is -22.2%, which is below its 3-year median of 6.5%.

How has Operating Margin changed over time?

Over the last 3 years, BioNTech SE’s Operating Margin has decreased from 73.4% to -22.2%. During this period, it reached a low of -40.7% on Dec 31, 2024 and a high of 73.4% on Sep 30, 2022.

Back to Top